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Abstract
Background The incidence of thyroid cancer is increasing globally. This is mainly due to the increase in the
detection of small papillary carcinomas, including papillary microcarcinomas (PMC) 1 cm or smaller. It was sug-
gested recently that PMCs are overdiagnosed and overtreated.
Methods In 1993, the author proposed a clinical trial to compare surgery and observation for low-risk PMC at
doctors’ meeting in Kuma Hospital, which was approved and the trial started in the same year. Patients choose
immediate surgery or observation. This paper shares our 22-year experience with the active surveillance of more than
2000 patients with low-risk PMC and compares the outcomes of immediate surgery with that of active observation.
Results The oncological outcomes of these management groups were similarly excellent. In our active surveillance
trial on 1235 patients, 8 % of patients showed tumor enlargement by 3 mm or more at 10 years of observation, and
3.8 % of the patients showed novel appearance of lymph node metastasis at 10 years. Patients 40 years or younger
tended to show progression of the disease. Patients with these slight progressions of the disease were successfully
treated with a rescue surgery. None of the patients in both study groups died of the disease. However, incidences of
unfavorable events, such as temporary vocal cord paralysis (VCP) and temporary and permanent hypoparathy-
roidism, were significantly higher in the immediate surgery group than in the observation group (4.1 vs. 0.6 %,
p\ 0.0001; 16.7 vs. 2.8 %, p\ 0.0001; and 1.6 vs. 0.08 %, p\ 0.0001, respectively). Permanent VCP occurred in
two of the surgery group.
Conclusions As a result, although we still offer two options, immediate surgery or observation, to patients with low-
risk PMC at Kuma Hospital, we now strongly recommend observation as the best choice.
Introduction
The incidence of thyroid cancer has been increasing rapidly
worldwide, due in major part to improvement of imaging
systems. A 2.4-fold increase was reported in the incidence
of thyroid cancer in the United States during the 30 years
from 1973 to 2002 [1]. This increase was due to the
increase in the incidence of papillary carcinoma, and the
incidences of follicular, medullary, and anaplastic carci-
noma remained stable. Looking more closely at the size of
papillary tumors, they found that the incidence of tumors
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2 cm or smaller had increased, while that of larger tumor
had remained stable. Papillary carcinomas 1 cm or smaller,
which are called papillary microcarcinomas (PMC), com-
prise 49 % of the cases. Although the incidence of thyroid
cancer increased 2.4-fold, the mortality from thyroid can-
cer remained stable. With these results, they concluded that
the increase was mostly due to the increase in detection of
small papillary cancer, and they suggested the possibility of
over-diagnosis and over-treatment. In 2014, they updated
their data, showing a 2.9-fold increase in thyroid cancer
incidence from 1975 to 2009, while the mortality from
thyroid cancer again remained stable [2]. In Korea, the
incidence of thyroid cancer increased by 15 times in
\20 years from 1993 to 2011 [3]. The increase was again
due to the increase in the incidence of papillary carcinoma,
and the thyroid cancer mortality remained stable. A similar
trend started much earlier in Japan, probably because
ultrasound examination and fine needle aspiration biopsy to
detect and evaluate thyroid nodules came to be used much
earlier in Japan than in the U.S. and Korea.
Regarding PMC, the following facts have been reported.
Many autopsy studies on subjects dying of non-thyroidal
diseases reported high incidences of latent thyroid cancer
[4–6]. If we look at papillary cancer larger than 3 mm,
which can be easily detected with ultrasound examination,
incidences of 3–5.2 % have been reported [7]. Ultrasound
examination allows detection of small thyroid tumors and
ultrasound-guided fine needle aspiration (FNA) made
diagnosis of these tumors possible, especially for papillary
carcinoma. Koji Takebe at Kagawa Cancer Examination
Center conducted a screening study using ultrasound
examination and ultrasound-guided FNA on subjects who
visited his center for the purpose of breast cancer screen-
ing. He found that 3.5 % of otherwise healthy Japanese
adult women had a small thyroid cancer [8]. This incidence
was similar to the incidence of latent thyroid cancer in
autopsy studies and more than 1000 times the prevalence,
3.1/100,000, of clinical thyroid cancer in Japanese women
at that time. The chances of detection are increasing
because of increasing use of imaging studies such as
ultrasound, CT scan, MRI, and PET. As a result, the
number of patients with PMC is increasing rapidly. This is
a worldwide phenomenon. Therefore, the question of how
to treat PMC has become a pressing clinical issue.
We do not know the natural history of PMC. One
hypothesis is that all PMCs are at an early stage of clinical
cancer, which may cause any harm or even kill the host.
Another hypothesis is that most PMCs stay small; they are
innocent or harmless cancers. Which hypothesis is true?
The latter seemed more likely to me, but some PMCs do
indeed grow. And of course, all advanced cancers start out
as small lesions. The critical question then becomes, ‘‘How
do we determine which small cancers are likely to cause
harm?’’ Assuming that doing surgery for all PMCs might
result in more harm than good, the hypothesis that obser-
vation without immediate surgery would provide an
answer, and that doing surgery for those who showed slight
progression would not be too late was tested in this study.
Methods and materials
The present author first proposed an observation without
immediate surgery clinical trial at a doctors’ meeting of
Kuma Hospital in 1993, where it gained approval, and the
trial started in the same year [9, 10]. The approach required
some strategic thinking regarding diagnosis by FNA, which
is very accurate with a positive predictive value of 98 %. In
1993, there were no guidelines for performing FNA. If we
did not perform FNA on patients with suspicious small
thyroid nodules, these patients might go and see other
doctors at other hospitals. These doctors might perform
FNA, and might recommend immediate surgery for thyroid
treatment. This could be unfortunate for the patients and
for the reputation of Kuma Hospital. After discussion on
this issue, we decided to perform ultrasound-guided FNA
on all suspicious nodules and to share the diagnosis with
patients. For patients with high-risk PMC, we recom-
mended surgery. For patients with low-risk PMC, we
proposed two options, immediate surgery or observation.
We gave the patients the current knowledge regarding
PMC such as high incidences of latent thyroid cancer, the
results of the thyroid cancer screening study by Dr. Takebe,
the prevalence of clinical thyroid cancer and good prog-
nosis of small papillary carcinoma following appropriate
surgery, and also the results of our observation trial in later
period of the trial. Patients chose one of the options. We
followed patients who chose observation with an ultra-
sound examination 6 months later and once a year there-
after. We recommended surgery if the tumor grew by
3 mm or more or if novel lymph node metastasis appeared.
High-risk PMC is defined as PMC having one or more
of the following: lymph node or distant metastasis,
extrathyroid extension, high-grade cytology, or growth
during a previous observation. We cautiously included
tumors located near the recurrent laryngeal nerve or
attached to the trachea in the high-risk category. Low-risk
PMC was defined as PMC having none of these features.
This definition was a kind of theoretical definition. In our
actual series of patients with PMC, none of them presented
with distant metastasis, and none of them showed high-
grade cytology.
Patients with PMC may present with cervical lymph
node metastases as shown in Fig. 1. These drawings are
reports by our sonographers at Kuma Hospital, which are
very useful for surgeons in designing surgical operation for
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the patients. Of course, such patients should be treated
appropriately. Total thyroidectomy, central node dissec-
tion, and left modified neck dissection were performed for
this patient. In another case, a 74-year-old man presented
with hoarseness. A laryngoscopy showed left vocal cord
paralysis (VCP). An ultrasound examination revealed a
small tumor with extrathyroid extension from the dorsal
surface of his left thyroid lobe (Fig. 2). A neck CT scan
showed a small tumor located exactly on the running
course of the left recurrent laryngeal nerve (RLN) (Fig. 2).
The FNA revealed papillary thyroid carcinoma. Total
thyroidectomy, central node dissection, resection of the left
RLN, and reconstruction of the nerve were performed for
this patient [11]. The surgical specimen showed PMC with
extrathyroid extension, consistent with the imaging studies.
These are typical features of high-risk PMC, which should
be treated appropriately.
As previously mentioned, we cautiously included
tumors located near the RLN or attached to the trachea in
the high-risk category. One of my colleagues, Yasuhiro Ito
specifically looked at on this issue and reported at the IAES
meeting [12]. Briefly, he found that the risk of tracheal
invasion of PMC 7 mm or larger was closely related to the
angle formed by the tumor and the trachea. An obtuse
angle was associated with high risk of tracheal invasion, a
nearly right angle or unclear with intermediate risk, and an
acute angle with low risk (Fig. 3). The risk of RLN inva-
sion was also associated with the presence or absence of a
Fig. 1 Sonograms and
drawings in the report of a
41-year-old woman with
papillary microcarcinoma with
many nodal metastases in the
left lateral neck compartment
Fig. 2 a Sonogram of a 74-year-old man with left vocal cord
paralysis revealing a small tumor extending from the dorsal surface of
his left thyroid lobe. b CT scan showing a small tumor located on the
course of the left recurrent laryngeal nerve
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normal thyroid rim in the direction closest to the RLN,
being high if the normal rim was absent, and low if the
normal rim was present (Fig. 3). In our series of PMC-
treated surgically, no PMC 6 mm or smaller had significant
invasion to the RLN or trachea. We recommended imme-
diate surgery for PMCs with high or intermediate risk
features.
Results and discussion
After 20 years’ experience, we are confident that patients
with low-risk PMC features should be considered candi-
dates for active surveillance.
Cancer Institute Hospital in Tokyo started a similar
active surveillance study for low-risk PMC 2 years after
our trial in Kuma Hospital [13]. Early results of these
studies were quite similar; \10 % of PMCs showed an
increase in size by 3 mm or more during the observation,
about 1 % of the patients showed novel nodal metastasis
during the trial, and none of the patients who underwent
surgery following the above events had recurrence [9, 13,
14]. With these promising results, Japanese Thyroid Tumor
Management Guidelines 2010 published by the Japanese
Association of Endocrine Surgeons and the Japanese
Society of Thyroid Surgery accepted ‘‘Observation for low-
risk PMC’’ as a management [15]. This became the first
guideline that accepted observation for low-risk PMC.
In 2014, we reported updated data of our active
surveillance trial on 1235 patients with low-risk PMC [16].
In terms of their clinical features, 90 % were female, 40 %
were 60 years or older, 14 % were younger than 40 years,
46 % were middle-aged, and 5 % had a family history for
papillary carcinoma. Thyroid antibody was positive in
32 % of the patients. Tumor size ranged from less than
5 mm to 10 mm. TSH-suppressive therapies was given in
only 4 % of the patients. Twelve percent of the patients had
multiple foci, 48 % had associated thyroid nodules, and
6 % were associated with Graves’ disease. The proportion
of patients whose PMC showed enlargement by 3 mm or
more was 8 % at 10 years of observation. The proportion
of the patients whose PMC showed novel appearance of
lymph node metastasis was 3.8 % at 10 years. One might
think that the appearance of nodal metastasis was a failure
of the observation trial. For patients who showed nodal
metastasis, we performed total thyroidectomy with central
and lateral neck compartment dissection. If these patients
had been treated at their presentation, the most likely
procedure would have been hemithyroidectomy with or
without paratracheal dissection. This procedure would not
be able to prevent the appearance of nodal metastasis in the
lateral compartment in most cases. Therefore, such patients
would require a second surgery, completion thyroidectomy
and lateral neck compartment dissection. We think that one
surgery is better than two surgeries, since the final out-
comes seem similarly good.
Dr. Mazzaferri reported that recurrence rate of thyroid
cancer after surgery was high in young and elderly patients
and low in middle-aged patients [17]. Although young
patients had high recurrence rate, their mortality from
Fig. 3 Schematic drawings on
the risks of invasion to the
tracheal and recurrent laryngeal
nerve of papillary
microcarcinoma
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thyroid cancer was low, while elderly patients had a high
recurrence rate and high mortality rate. We studied the
postoperative thyroglobulin status and thyroglobulin-dou-
bling time according to age at surgery in 426 patients with
advanced papillary carcinoma who underwent total thy-
roidectomy in Kuma Hospital [18]. When these patients
were treated, only those with advanced disease underwent
total thyroidectomy in Kuma Hospital. Detectable serum
thyroglobulin postoperatively indicated biochemically
persistent disease for these patients. About 40 % each of
the patients younger than 40 years and those 60 years or
older had biochemically persistent disease postoperatively,
while this proportion was 27 % in patients of age 40–59.
The proportion of patients with a thyroglobulin-doubling
time shorter than 2 years, indicating the presence of rapidly
growing hidden metastasis, was low in young (2.4 %) and
middle-aged patients (3.9 %), and was high in elderly
patients (19.3 %). Interestingly, about half or even more
than half of patients with biochemically persistent disease
in young and middle-aged patients had a decrease in their
serum thyroglobulin values over time (50 and 69 %,
respectively), while this proportion was low, at 27 %, in
elderly patients. These findings were consistent in some
sense with the report by Mazzaferri et al. Age is an
important prognostic factor for papillary carcinoma. The
UICC/AJCC TNM staging system divides patients with
differentiated thyroid carcinoma into young and old groups
with the cutoff at 45 years. Our data indicate that dividing
patients to three age groups with two cutoffs at 40 and
60 years is more appropriate [18]. At any rate, when I first
proposed the observation trial, I knew that the prognosis of
elderly patients with clinical thyroid cancer was poorer
than younger patients. So, I had some concern about
including elderly patients with low-risk PMC in this trial.
However, the actual outcome was different from what
expected. PMCs in patients younger than 40 years tended
to show an increase in size, while PMCs in patients
60 years or older rarely increased in size. PMCs in the
40–59 year age group were in between (Table 1) [16].
Multivariate analysis for size enlargement of PMC
revealed that young age was the only significant factor, and
that family history and multiple foci were not significant
factors. Patients younger than 40 years tended to show
novel lymph node appearance, while middle-aged and
elderly patients were unlikely to show nodal metastasis
(Table 1) [16]. Multivariate analysis for novel appearance
of lymph node metastasis revealed that an age younger than
40 year was the only significant factor, and that family
history and multiple foci were not significant factors.
TSH-suppressive therapy was performed for only 51
patients. Of them, only one patient (2 %) showed an
increase in the size of PMC, while 57 patients (4.8 %) of
the remaining 1187 patients who did not have this therapy
showed progression of the disease, tumor enlargement, or
nodal metastasis. This difference did not reach signifi-
cance, possibly due to the small number of patients with
TSH-suppressive therapy.
After initiating the observation trial, 186 patients
underwent thyroid surgery for various reasons, including a
change in the patient’s mind. None of these patients had
recurrence of the disease or died from the disease, except
for one who developed PMC in the contralateral lobe fol-
lowing hemithyroidectomy. During the active surveillance,
6 patients died of unrelated diseases such as breast cancer,
lung cancer, and brain hemorrhage [16].
From the oncological outcome of our active surveillance
of low-risk PMC, we can say that those age 40 and older
are better candidates for observation than young patients.
Although the progression rates are slightly higher in young
patients, we think that they also can be candidates for
observation, since the final outcome was excellent.
My young colleague Hitomi Oda looked into the nega-
tive side of our two management practices for low-risk
PMC. She reported on this issue as a poster in the same
IAES meeting where this paper was originally presented
[19]. In brief, 2153 patients with low-risk PMC were seen
from February 2005 to August 2013 in Kuma Hospital. Of
them, 974 patients (45 %) chose immediate surgery. Five
patients had regional recurrences after the surgery, which
were treated successfully. After surgeries, 5 patients died
of unrelated diseases. Other than these 5, 969 patients were
alive without evidence of disease. 1179 patients (55 %)
chose observation. After a certain period of observation, 94
patients underwent thyroid surgery for various reasons.
One of them had a regional recurrence, which was treated
successfully. All 94 patients were alive and free of the
disease. During the active surveillance, 3 patients died of
unrelated diseases, and the remaining 1082 patients were
alive without cancer progression. Thus, the oncological
outcomes of both management groups were both excellent.
Table 1 Proportion of the patients with low-risk papillary micro-
carcinoma who showed progression of the disease during the active
surveillance according to age
Age at presentation
\40 years (%) 40–59 years (%) C60 years (%)
Enlargementa
At 5 years 9.1 5.0 4.0
At 10 years 12.1 9.1 4.0
Nodal metb
At 5 years 5.2 1.4 0.5
At 10 years 16.1 2.3 0.5
a Enlargement of the tumor by 3 mm or more
b Appearance of novel lymph node metastasis
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However, the incidences of unfavorable events such as
temporary VCP, temporary hypoparathyroidism, and per-
manent hypoparathyroidism were significantly higher in
the immediate surgery group than in the active surveillance
group (4.1 vs. 0.6 %, p\ 0.0001; 16.7 vs. 2.8 %,
p\ 0.0001; and 1.6 vs. 0.08 %, p\ 0.0001, respectively)
[19]. Unfortunately, 2 (0.2 %) of the immediate surgery
group incurred permanent VCP postoperatively. One was
caused by accidental transection of the RLN. Transected
nerve ends were anastomosed immediately; however, the
vocal cord on that side remained immobile. The other was
accidental ligation of the RLN. The ligation thread was
released, but VCP persisted. These operations were per-
formed by well-experienced endocrine surgeons at Kuma
Hospital, Center for Excellence in Thyroid Care. You
might think that surgeries for PMC are simple and easy.
However, human errors can occur even while performing
simple and easy actions. This is the reality. If surgeries had
been done by less experienced surgeons, the incidences of
these unfavorable events would have been much higher.
A 49-year-old woman came to see me after she under-
went hemithyroidectomy and neck dissection for PMC that
was detected by a thyroid cancer screening examination.
The surgery was done at another hospital in other prefec-
ture. Immediately after the operation, she got bilateral
VCP. Several years later when she caught a cold, pneu-
monia developed and she required a tracheostomy. None of
our patients on the active surveillance developed even
unilateral VCP during the observation. The tragedy of
bilateral VCP would never have occurred during active
surveillance for appropriately selected patients.
Figure 4 shows sonograms of a woman with PMC at her
presentation when she was 46-years old and those taken
18 years later. Although the qualities of the pictures differ
each other because of the improvement of ultrasound
machine during this long interval, the size and shape of
PMC show very little change. This was a very common
finding of the active surveillance.
There are limitations to our study. Assignment to
observation and immediate surgery groups was not ran-
dom, but based on the wishes of the patient; hence, some
bias might exist in the results.
In conclusion, the oncological outcomes of immediate
surgery and active surveillance for PMC were similarly
excellent. However, the incidence of unfavorable events
was significantly higher in the immediate surgery group
than in the active surveillance group. The title being given
to my talk was ‘‘Clinical Trials of Active Surveillance of
PMC of the Thyroid: Is it good?’’ Now, I say, ‘‘Yes! It is
good for the patients with low-risk PMC.’’ Today at Kuma
Fig. 4 Sonograms of a woman with papillary microcarcinoma at the presentation when she was 46-years old and those 18 years later. Note that
the size and shape of the tumor did not change much. Left two images, at presentation; right two, 18 years later
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Hospital, although we still offer two options for patients
with low-risk PMC, immediate surgery or active surveil-
lance, we recommend active surveillance as the best choice
for the patients.
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